iShares Neuroscience and Healthcare ETF Rating $33.66 -0.45 (-1.32%) As of 09:39 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatings iShares Neuroscience and Healthcare ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.IBRN Aggregate RatingModerate Buy 2.78Holdings in IBRN have an aggregate rating of Moderate Buy based on 363 analyst ratings issued in the past year covering 21 companies (73.5% of the portfolio).IBRN Aggregate Price Target$34.11High Prediction$34.11Average Prediction$34.11Low Prediction$34.11Holdings in IBRN have an aggregate price target of $34.11 and a range of $34.11 to $34.11 covering 21 companies (73.5% of the portfolio).IBRN Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by iShares Neuroscience and Healthcare ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 IBRN Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings5.28%DNTHDianthus Therapeutics$93.84+0.4%Moderate Buy$129.83 38.4%152.503 of 5 stars5.00%PRAXPraxis Precision Medicines$281.980.0%Moderate Buy$612.42 117.2%202.5169 of 5 starsAnalyst Forecast4.90%ACADACADIA Pharmaceuticals$22.62-11.0%Moderate Buy$34.36 51.9%184.5144 of 5 starsPositive NewsAnalyst Forecast4.58%SRRKScholar Rock$49.91+0.1%Moderate Buy$66.69 33.6%183.4793 of 5 starsAnalyst ForecastGap Down4.49%BIIBBiogen$226.69-0.4%Moderate Buy$230.14 1.5%322.5365 of 5 stars4.47%ARGXargenex$947.38+0.2%Moderate Buy$1,158.61 22.3%244.5936 of 5 stars4.42%XENEXenon Pharmaceuticals$36.71+0.4%Moderate Buy$70.93 93.2%172.5098 of 5 stars4.37%ALKSAlkermes$41.43-1.7%Moderate Buy$54.47 31.5%193.525 of 5 starsNews CoverageAnalyst Forecast3.92%ARWRArrowhead Pharmaceuticals$66.15-1.2%Moderate Buy$98.31 48.6%142.6406 of 5 stars3.76%PTCTPTC Therapeutics$62.03-0.5%Moderate Buy$99.08 59.7%153.588 of 5 starsAnalyst Forecast3.72%NBIXNeurocrine Biosciences$137.45-1.5%Moderate Buy$201.09 46.3%244.7525 of 5 starsPositive News3.71%EWTXEdgewise Therapeutics$40.58-1.1%Moderate Buy$51.33 26.5%113.3958 of 5 starsAnalyst Forecast3.57%AXSMAxsome Therapeutics$192.55-0.5%Moderate Buy$271.85 41.2%223.8081 of 5 starsAnalyst Forecast3.28%DNLIDenali Therapeutics$20.27-0.9%Moderate Buy$35.85 76.8%163.5404 of 5 starsPositive News2.56%DYNDyne Therapeutics$16.16-0.4%Moderate Buy$32.17 99.0%163.1864 of 5 stars2.52%AXGNAxoGen$42.93-0.9%Moderate Buy$51.56 20.1%122.4831 of 5 stars2.43%SUPNSupernus Pharmaceuticals$43.39Hold$62.83 44.8%73.74 of 5 starsAnalyst Forecast2.27%SRPTSarepta Therapeutics$18.99+0.2%Hold$24.07 26.7%193.6274 of 5 stars1.68%BHVNBiohaven$13.50-1.2%Moderate Buy$18.69 38.4%172.9248 of 5 stars1.31%RAPPRapport Therapeutics$34.130.0%Buy$66.25 94.1%132.5555 of 5 starsNews CoverageAnalyst Forecast1.30%TSHATaysha Gene Therapies$4.82-1.8%Buy$12.77 164.9%152.9109 of 5 starsAnalyst Forecast This page (NYSEARCA:IBRN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Neuroscience and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Neuroscience and Healthcare ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBRN Stock Alerts